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This paper reviews the therapeutically beneﬁcial eﬀects of progressive resistance exercise (PRE) on Parkinson’s disease (PD). First,
this paper discusses the rationale for PRE in PD. Within the ﬁrst section, the review discusses the central mechanisms that underlie
bradykinesia and muscle weakness, highlights ﬁndings related to the central changes that accompany PRE in healthy individuals,
and extends these ﬁndings to individuals with PD. It then illustrates the hypothesized positive eﬀects of PRE on nigro-striatal-
thalamo-cortical activation and connectivity. Second, it reviews recent ﬁndings of the use of PRE in individuals with PD. Finally,
knowledge gaps of using PRE on individuals with PD are discussed along with suggestions for future research.
1.Introduction
The standard treatment for Parkinson’s disease (PD) is phar-
macologic treatment with levodopa, a precursor to do-
pamine. However, continued treatment with levodopa is
associated with motor side eﬀects such as dyskinesias and
motor ﬂuctuations. Until an oral formulation of levodopa
without the accompanying motor side eﬀects is formulated,
surgical options oﬀer some relief. Typically, surgery is
reserved for when the disease and the side eﬀects due
to medication are severely disabling. Currently, the most
common surgical option is high-frequency deep brain
stimulationofthesubthalamicnucleusortheinternalglobus
pallidus [1–4]. Despite the substantial clinical beneﬁts of
surgery, surgical treatment is not without complications,
which occur in up to 50% of individuals with PD who
undergo deep brain stimulation [2, 5]. These complications
include device/surgery-related infections, cognitive decline,
depression, speech diﬃculties, gait disorders, and postural
instability [2, 5]. Therefore, there is merit to exploring treat-
ment options that may be used as adjuncts to pharmacologic
and surgical treatments prescribed in PD. One such option is
exercise, speciﬁcally progressive resistance exercise (PRE).
This review paper will ﬁrst discuss the rationale for PRE
in PD speciﬁcally related to bradykinesia and muscle weak-
ness. Then it will review recent ﬁndings related to the use of
PRE in individuals with PD. Finally, it will identify gaps in
knowledge of using PRE in individuals with PD and makes
suggestions for future research.
2. Rationale for Progressive
Resistance Exercise
This section will set up the basis for PRE as a therapeutic
intervention in PD. To do so, we will outline the underlying
mechanisms for the motor symptoms that can be treated2 Parkinson’s Disease
withPRE.Wewillfocusprimarilyonthecentralmechanisms
that underlie bradykinesia and muscle weakness in PD.
Then we will discuss the central changes that accompany
PRE and hypothesize how these changes might modify the
central mechanisms that underlie bradykinesia and muscle
weakness. We will conclude this section with our rationale
for the use of PRE in individuals with PD.
2.1. Bradykinesia and Muscle Weakness. Bradykinesia refers
to the slowness of a performed movement [6]. Bradykinesia
is a primary motor symptom of PD, which is also consid-
ered the most functionally debilitating symptom and is a
consistent feature of the disease [7]. Muscle weakness, which
is a reduction in the amount of force generated by muscle
contraction, is often observed in individuals with PD. In fact,
several studies have demonstrated that individuals with PD
exhibit muscle weakness [8–15]. We have shown that this
weakness is exaggerated in the extensor muscles, speciﬁcally
extensors of the elbow [8, 16]. Additionally, muscle weakness
has also been observed across various muscle groups in the
trunk [11], upper limbs [14], and lower limbs [9, 10, 13, 14].
In PD, the idea that bradykinesia and weakness are
related can be derived from the fact that bradykinesia
and muscle weakness might share common underlying
mechanisms. Central to the pathophysiology of PD is the
known nigral dopaminergic deﬁcit that results in an increase
in tonic inhibition of the thalamus and reduction in the
excitatory drive to the motor cortex [17]. This, in turn, may
result in disruption of the cortical activation of the muscle
[18–21] and may manifest as bradykinesia and muscle
weakness. Further, muscle power, the product of movement
velocity and muscle torque, is reduced in individuals with
PD [13]. Also, torque production during isokinetic muscle
strength testing in individuals with PD has been shown to
vary with movement velocity. Nogaki et al. found that in
individuals with PD, no diﬀerence was observed in peak
torque between the more and the less aﬀected side for slower
movements, while for faster movements, the more aﬀected
side was signiﬁcantly weaker than the less aﬀected side [22].
Therefore, reduction in muscle power is indicative of deﬁcits
in either strength, movement speed, or both and strengthens
the proposed relationship between bradykinesia and muscle
weakness.
Given that the muscle is the ﬁnal target of cortical
output during movement and force production, analyzing
the electromyographic (EMG) activation patterns can pro-
vide insight into hypothesized impairments that underlie
bradykinesia and muscle weakness. We have shown that
in individuals with PD, EMG activation patterns during
ballistic movements and isometric actions are abnormal and
reﬂect impaired activation of the muscle. Muscle activation
patterns during ballistic movement in individuals with PD
are abnormal in four signiﬁcant ways. First, muscle activa-
tion patterns show increased variability when compared to
age- and sex-matched healthy individuals [23, 24]. Second,
in contrast to healthy individuals, the ﬁrst agonist burst
duration does not systematically increase with movement
distance [23]. Third, the magnitude of the ﬁrst agonist
burst, early in the disease, is similar to that observed in
healthy individuals; however, as the diseases progresses,
the magnitude of the ﬁrst agonist burst is modulated less
with increasing movement distance [23]. Fourth, multiple
agonist bursting is observed during the acceleration phase of
movement, and the number of agonist bursts increases with
increasing the movement distance [23, 24]. During isometric
actions, individuals with PD manifest deﬁcits throughout
the task. At the very beginning of the task, they exhibit
decreased rate of torque generation and decreased initial
phasic agonist EMG activation, which results in prolonged
torquerisetimesanddelayedpeaktorque[16].Inthemiddle
of the task, during steady-state contraction at 25%, 50%,
and 75% of maximal voluntary contraction (MVC), the
dominant frequency in the EMG spectrogram in individuals
with PD stays fairly constant at ∼10Hz [25]. In healthy
individuals, however, the dominant frequency is higher and
increases with the increase in isometric torque generation,
that is, the dominant frequency shifts from ∼18 to 25Hz
when isometric torque generation increases from 25% to
75% of MVC [25]. At the end of the task, the rate of release
ofmusclecontractionisalsoprolonged,andtorquefalltimes
are increased in individuals with PD [26].
The abnormal EMG activation patterns discussed above
can be partly explained in terms of an impairment in the
corticospinal activation of the muscle, speciﬁcally, impair-
ments in variability, intensity, and frequency of the corti-
cospinal activation of the muscle. Increased variability in
the corticospinal activation of the muscle could lead to
variability in motor unit recruitment and result in increased
EMG variability [27]. This increased variability in motor
unit recruitment could impair coordinated relaxation of
actively contracting motor units, contributing to prolonged
deceleration phases during movement and prolonged relax-
ation times during isometric torque generation. Reduction
in the intensity of the corticospinal activation of the muscle
[28] may result in impaired motor unit recruitment and
could contribute both to bradykinesia and muscle weakness.
For instance, impaired motor unit recruitment during
movement could result in reduced angular impulse during
the acceleration phase of a movement and contribute to
bradykinesia, and impaired motor unit recruitment during
isometric torque generation could result in reduced peak
torque and contribute to muscle weakness.
Alterations in the frequency of the corticospinal activa-
tion of the muscle could also explain some of the abnor-
mal EMG patterns observed in individuals with PD. In
healthy subjects the corticospinal activation to the muscle
is characterized by three primary frequencies, that is, 10Hz,
20Hz, and 40Hz [29, 30]. The magnetoencephalic (MEG)
power spectrum is dominated by ∼20Hz oscillations during
weak contractions and ∼40Hz oscillation during strong
contractions [29]. Similarly, the mean power in the EMG
power spectrum increases from 10Hz to 25Hz with increase
in percent MVC from 10% to 80% of MVC [31]. In
untreated (de novo) individuals with PD relative to age-
and sex-matched healthy individuals, resting state cortical
activity in the 8–10Hz band is increased, while activity in
the 30–48Hz band is reduced [32]. Further, in individuals
with PD, the EMG power spectrum is dominated by powerParkinson’s Disease 3
in the low-frequency band (∼10–15Hz) [25, 26, 29], and the
MEG-EMG coherence is strong in this low-frequency band
with the MEG signal leading the EMG signal by ∼15–38ms
[29]. Thus, one could hypothesize that if the cortical signal
to the muscle is dominated by low-frequency oscillations,
then this limits the ability to recruit larger, high-frequency
motor units, which are required to rapidly generate torque
during ballistic movements and generate maximal torque
during isometric torque generation. The evidence reviewed
in this and the previous two paragraphs suggests that EMG
patterns are abnormal in individuals with PD, and one likely
explanation for these observed EMG abnormalities is deﬁcits
inthevariability,intensity,andfrequencyofthecorticospinal
activation of the muscle.
Another factor that could contribute to muscle weakness
in individuals with PD is reduced muscle mass. Evidence
that muscle mass is reduced in PD is provided by Petroni
and colleagues [33]. They reported that midarm muscle
circumference was below the 10th percentile in 23% of
individuals with advanced PD between 65 and 75 years of
age [33]. On the other hand, evidence that this is not the
case is provided by Markus and colleagues [34]. They found
that even though body mass index and skin fold thickness,
relative to age- and sex-matched healthy individuals, were
reduced in individuals with PD, midarm circumference was
not diﬀerent from healthy individuals. Thus, the authors
concluded that decrease in body mass index was due to a loss
of fat and not due to a loss of muscle mass.
It is important to note that not only does PD cause
weakness, but it is highly likely that muscle weakness and
functional limitations such as postural instability and gait
disturbances lead to reduced physical inactivity as a com-
pensatory mechanism to minimize the likelihood of falls
[35]. Therefore, physical inactivity can contribute to muscle
weakness and lead to a vicious cycle between muscle
weakness and physical inactivity [36].
Even though we cannot discount muscle mass and
c h a n g e si nm u s c l ep r o p e r t i e sa sl i k e l yc o n t r i b u t o r st om u s c l e
weakness, it is our stand that the primary contributors to
muscle weakness are central in origin and are related to
dopaminergic deﬁcits. This is evidenced by the fact that both
anti-Parkinsonian medication and deep brain stimulation
result in signiﬁcant improvement in movement speed [24,
37]andsigniﬁcantgainsinmusclestrengthinrelativelyshort
amounts of time (not longer than 90 minutes) [16, 38, 39].
Given that the minimum amount of time required to notice
appreciable hypertrophy is at least 20 days [40], it is highly
unlikely that the immediate strength gains brought about by
anti-Parkinsonian medication or deep brain stimulation are
caused by gains in muscle mass.
The question that remains is the extent to which bradyki-
nesia and weakness can be compensated for. We have shown
that levodopa and/or deep brain stimulation of the subthala-
mic nucleus improves bradykinesia and/or muscle strength
[24, 38, 39]; however, bradykinesia is not normalized [24,
37]. Moreover, surgical interventions carry signiﬁcant risks,
while medication becomes progressively less eﬀective, and
the side eﬀects of medication get progressively worse over
time. Therefore, until a cure for PD can be identiﬁed, there
is a compelling need to develop interventions that improve
the signs and symptoms of the disease and slow down the
rate at which the signs and symptoms of the disease worsen.
One such intervention is PRE, which may be a beneﬁcial
and cost eﬀective adjunct treatment in managing PD. As
such, if PRE is to be beneﬁcial for individuals with PD,
it should bring about central changes that potentially alter
nigro-striatal-thalamo-cortical activation and connectivity.
Since this has not yet been studied in individuals with PD,
we will discuss the central changes that accompany PRE
in healthy young and elderly individuals and extend these
ﬁndings to individuals with PD.
2.2. Central Changes That Accompany Progressive Resistance
Exercise. The evidence for the central changes that accom-
pany PRE is threefold [41]. First, gains in muscular strength
appear before noticeable muscle hypertrophy [41, 42]. After
commencing a PRE protocol, strength gains appear as
early as 5 days [43], but muscle hypertrophy appears no
earlier than 20 days [40]. Therefore, the initial gains in
muscle strength cannot be explained by measurable muscle
hypertrophy. Instead, a likely explanation for the observed
strength gains is the central changes that accompany PRE.
Second, cross-education (i.e., improved performance in the
untrainedlimb)isoftenobserved[41].Munnandcolleagues,
in their meta-analysis that included 13 studies, concluded
that unilateral PRE brings about a 7% increase in strength
in the untrained contralateral limb [44]. Given that this
cross-education eﬀect is accompanied by increase in muscle
surface EMG, but is not accompanied by gains in muscle
size, it is likely to be brought about by the central changes
that accompany PRE [42, 45]. Third, improvements in per-
formance following PRE are both speciﬁc and generalized.
The argument for speciﬁcity arises from the fact that short-
termdynamicstrengthtrainingresultsinsigniﬁcantlygreater
gains in dynamic strength, while isometric strength gains are
marginal [46]. While the argument for generalizability arises
from the fact that short-term strength training that focuses
on increasing isometric strength also improves movement
coordination during an untrained task [47]. Thus, both
speciﬁc and generalizable motor learning eﬀects of PRE
provide a third line of evidence for the central changes that
accompany PRE.
Further evidence for the central changes that accompany
PRE comes from studies employing transcranial magnetic
stimulation (TMS), electroencephalography (EEG), func-
tionalmagneticresonanceimaging(fMRI),andmuscleEMG
activationpatterns.UsingTMS,Carrollandcolleaguesfound
that for the same level of torque, the amplitude of the motor
evoked potential was signiﬁcantly reduced following a 4-
week PRE program [48]. They concluded that resistance
training altered the functional properties of the spinal cord
circuitry, and fewer motor neurons were recruited for similar
levels of pretraining torque. Using EEG, Falvo and colleagues
found that the movement-related cortical potentials were
signiﬁcantly attenuated following a 3-week PRE program
[49]. They concluded that PRE reduced the neural eﬀort
required to move similar levels of pretraining loads. Using
fMRI, Liu-Ambrose and colleagues found that in elderly4 Parkinson’s Disease
women, following PRE, percent signal change signiﬁcantly
increased in the left anterior insula and the anterior portion
of the left middle temporal gyrus [50]. They concluded that
PRE could facilitate functional plasticity in the cortex. Using
EMG, several studies have shown that muscle activation
patterns change after PRE [42, 49, 51–54]. These muscle
activation changes following PRE include an increase in
the EMG activation [40, 53, 54], possibly due to increased
motor unit recruitment [55–57], increased ﬁring rate [57,
58], and improved synchronization [52, 59]; a reduction in
the EMG activation to torque ratio, that is, reduction in
EMG activation relative to the amount of torque produced
[60]; a reduction in the variability associated with the
timing, amplitude, and duration of muscle activity [47]; a
reduced agonist-antagonist coactivation [61]. In addition,
central changes accompanying PRE have been inferred using
the H-reﬂex to examine motor neuron reﬂex excitability.
Holtermann and colleagues found that the amplitude of
the H-reﬂex increased following a 3-week PRE program in
healthy individuals [62]. Further, they found that the H-
reﬂex increase in amplitude was associated with an increased
rate of force development. This could provide a neurophys-
iological basis for PRE improving bradykinesia in PD. The
exact mechanisms underlying the observed increase of the
H-reﬂex amplitude are not yet known however. The authors
suggested that one possibility is that the reﬂex excitability of
the motor neuron pool may be enhanced following PRE.
It should be noted that some of the neural changes
discussed in the preceding paragraphs may be aﬀected by
factors such as age, sex, the muscle group trained, and their
interactions [63, 64]. For instance, following PRE, upper
and lower body strength gains are greater in young than in
healthy elderly individuals [63]. Also, upper body strength
gainsaregreaterinmenthaninwomen;however,lowerbody
strength gains are not diﬀerent between men and women
[63].
In summary, PRE can bring about changes throughout
the neural axis. Currently, none of the central changes
that accompany PRE discussed previously in this sec-
tion have been researched in individuals with PD. Even
though improvements in neuromuscular function have been
observed in individuals with PD, from a physiological per-
spective, further research is required to elucidate the central
changes that accompany PRE that could mitigate the motor
and nonmotor symptoms observed in PD.
Brain regions where PRE could potentially alter activity
includethemotorcortex,theposteriorputamen,theinternal
globus pallidus (GPi), and the subthalamic nucleus (STN)
(Figure 1). Fisher and colleagues recently demonstrated
motor cortical changes following body-weight-supported
treadmill training in individuals with PD [65]. They
showed that cortical hyperexcitability, which is consistently
observed in individuals with PD, is reversed following body-
weight-supported treadmill training [65]. Petzinger and
colleagues have also shown an increase in the stimulus-
evoked dopamine release within the dorsolateral striatum
following intensive treadmill training in 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine- (MPTP-) lesioned mice [66].
Because the dorsolateral striatum is engaged to a high degree
during fore- and hind-limb movements during treadmill
exercise, they attributed the observed striatal plasticity to
use-dependent synaptic plasticity.
Similarly, there may also be use-dependent synaptic
plasticity in the putamen, the GPi, and the STN following
PRE. Our lab has conducted a series of studies in which we
have shown that nuclei within the basal ganglia scale with
the performance of diﬀerent force producing tasks in both
healthy individuals and individuals with PD. Speciﬁcally,
we have shown that both the globus pallidus and the STN
increase percent signal change when generating progressively
larger forces in healthy individuals [67]. We have also shown
that individuals with PD have a reduced percent signal
change in all nuclei of the basal ganglia during an isometric
force production task, even early in the disease process
whenindividualshavenotyetstartedtheiranti-Parkinsonian
medication [68]. In addition, blood-oxygen-level-dependent
activityinthenucleiofthebasalgangliawascorrelatedtothe
motorsectionoftheUniﬁedParkinson’sDiseaseRatingScale
(UPDRS) [69]. The symptom with the highest correlation
with basal ganglia activity was bradykinesia. Thus, if PREs
were shown to alter the motor section of the UPDRS and
bradykinesia, then it is possible that the neuronal activity of
the basal ganglia would also be altered by PRE.
Figure 1 illustrates the hypothesized positive eﬀects PRE
might have in individuals with PD by possibly altering
activity and connectivity in cortical and subcortical regions.
It should be noted that these eﬀects of PRE on activity and
connectivity in cortical and subcortical regions are purely
speculative,astherearenoinvivostudiesthathaveexamined
this relationship. As can be clearly seen from the ﬁgure
however, the basal ganglia are strategically positioned to
inﬂuencecorticaloutputandmodulatecontrolofmovement
and force. As such, we suggest that one potential reason for
why PRE could be therapeutically beneﬁcial for individuals
with PD is that it may alter activity in the cortex and the
basal ganglia, and connectivity between and within these
regions. Advances in experimental techniques, such as TMS,
EEG, fMRI, positron emission tomography (PET), diﬀusion
tensor imaging (DTI), and EMG and reﬂex analyses, aﬀord
the possibility of testing hypotheses related to the eﬀect of
PRE on neural activity, neural connectivity, and structural
integrity in vivo,i nh u m a n s .Figure 1 shows the outcomes
and tools that can be used to empirically determine the
eﬀects of PRE in speciﬁc brain regions. To elaborate, changes
in cortical excitability can be measured using TMS, while
changes in cortical activity and intracortical connectivity can
be measured using EEG. Functional MRI can be used to
identify blood-oxygenation-level-dependant signal changes
incorticalandsubcorticalregionsfollowingPRE.PETcanbe
used to investigate the eﬀect of PRE on dopamine synthesis,
transport, and usage. Diﬀusion tensor imaging can help
elucidate hypotheses related to the changes in structure in
corticalandsubcorticalregions,namely,thesubstantianigra,
the STN, and the thalamus. Reﬂex and EMG analyses can
be used to identify reﬂex changes, such as change in H-
reﬂex amplitude, and changes in EMG activation patterns
to infer central changes following PRE. Prior to embarking
on empirical veriﬁcation of some of the ideas presented inParkinson’s Disease 5
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Figure 1: Hypothesized central eﬀects PRE might have in the cortex, basal ganglia, and spinal cord and the tools that can be used to examine
these hypothesized changes. TMS, transcranial magnetic stimulation; EEG, electroencephalography; fMRI, functional magnetic resonance
imaging;PET:positronemissiontomography;DTI:diﬀusiontensorimaging;EMG:electromyography;SNc:substantianigraparscompacta;
GPe: external globus pallidus; GPi: internal globus pallidus; STN: subthalamic nucleus.
this paragraph, researchers are cautioned on the technical
diﬃculties, limitations, and the complications of the above-
mentioned methods (for a recent detailed review, see Carroll
et al. [70]).
In conclusion, the rationale for the use of PRE in PD
is fourfold. First, as discussed above, individuals with PD
exhibit muscle weakness. PRE can signiﬁcantly increase the
torque- and power-generating capacity of the muscle, thus
directly aﬀecting muscle weakness. Even though other forms
of exercise such as aerobic exercise provide substantial health
beneﬁts, they do not improve muscle strength by design.
Improvements in muscle strength and power have signiﬁcant
impact on bradykinesia [71] and could also facilitate inde-
pendence in the community, improve functional mobility,
and may reduce the risk of falls [72]. Second, exercise
interventions in general have been shown to enhance cortical
activity, possibly beneﬁcially altering variability, intensity,
and frequency components of the corticospinal activation
of the muscle [47–49, 73]. This could signiﬁcantly impact
bradykinesiainindividualswithPD[65].Third,exercisemay
slow down the rate at which the UPDRS scores increase. The
UPDRS is the clinical gold standard for assessing the severity
and progression of symptoms in PD and for evaluating
novel therapies, with higher scores reﬂecting more severe
disease. Reuter and colleagues have shown that a 14-week,
intense, multimodal exercise training program can bring
about ∼12 point reduction in the motor UPDRS scores
[74]. Additionally, physical activity has been associated with
increasing the survival rate of individuals with PD [75].
Finally, there may well be additional beneﬁts for the non-
motor symptoms of PD, such as executive function, mood,
and quality of life.
3.ProgressiveResistanceExerciseinPD
Rehabilitation research studies in individuals with PD dem-
onstrate that PRE can have a positive eﬀect on muscle size
[76], muscle strength [15, 71, 76–78], muscular endurance
[77, 79], and neuromuscular function [71, 76–79]. To date,
only one study [76] has quantiﬁed changes in muscle size
in individuals with PD. Dibble and colleagues observed a
6% increase in muscle volume, measured using volumetric
magnetic resonance imaging, after a 12-week eccentric PRE
program [76]. Eccentric PRE training involves the use of
eccentric muscle activity, that is, the active lengthening of
muscles when an external load is imposed; consequently,
work is done on the muscle [80]. The rationale used by
Dibble and colleagues for using eccentric PRE is that for the
same amount of work (i.e., force × distance), high levels of
force are generated with minimal oxygen consumption [81].
With regard to muscle strength, several studies have
demonstrated signiﬁcant gains in muscle strength following
PRE in PD [15, 71, 76–78]. For instance, improvements
in strength were observed by Hirsch and colleagues in
a randomized controlled trial that compared a 10-week
balance training protocol to a 10-week balance training plus
PRE protocol [78]. At the end of 10 weeks, they observed
signiﬁcant improvements in strength in knee extension, knee6 Parkinson’s Disease
ﬂexion, and ankle plantar ﬂexion in the balance plus PRE
group. When the strength measures were combined across
the knee and ankle, they observed a 52% increase in strength
frombeforetoaftertreatmentinthebalanceplusPREgroup.
In another randomized placebo-controlled trial, Hass and
colleagues demonstrated signiﬁcant gains in strength and
endurance in upper body muscles, following a 12-week PRE
program supplemented with creatine monohydrate [77].
Improvement in endurance was observed by Scandalis and
colleaguesfollowingan8-weekPREprogramthatwasgeared
toward the lower body [79]. They found improvements
in the total number of abdominal crunches that could be
performed at one time. They also observed improvements in
lower limb performance, which was quantiﬁed as a product
of repetitions and weight. Next, we will review the evidence
that supports positive changes in neuromuscular function
that accompany strength gains in individuals with PD fol-
lowing PRE.
From a rehabilitation perspective, it is critical that
strength gains bring about corresponding improvements in
neuromuscular function, such as gait, stair climbing, timed
up and go, and postural stability. To this end, recent studies
have shown signiﬁcant improvement in neuromuscular
function following PRE interventions in PD. First, improve-
ments in gait have been reported. Three-dimensional gait
analyses following an 8-week PRE program demonstrated
that individuals with PD increased their gait velocity, stride
length, and head angle relative to the ﬂoor during midstride
[79]. Similar ﬁndings of increased gait velocity were also
reported by Dibble and colleagues following a 12-week
eccentric PRE intervention [71, 76]. The functional gait
outcomes included the six-minute walk, ten-meter walk,
timed up and go, and stair ascent and descent times. They
observed that individuals with PD signiﬁcantly improved
gait velocity and increased the distance walked in six-
minutes, reduced the time taken to walk ten meters, reduced
the time taken to complete the timed up and go, and reduced
stair descent times. Their ﬁndings led them to conclude that
progressive resistance eccentric exercise could signiﬁcantly
impact bradykinesia. Second, improvement in postural sta-
bility has been reported. Hirsch and colleagues showed that
individuals with PD demonstrated an improved ability to
maintain balance during destabilizing conditions following a
10-weekbalanceplusPREintervention[78].Third,improve-
ment in patient-perceived quality of life has been reported.
Even though quality of life is not a direct measure of neuro-
muscular function, it is reasonable to assume that improved
neuromuscular function might contribute to improved qual-
ity of life. Dibble and colleagues found that eccentric PRE
signiﬁcantly improved patient-perceived quality of life as
measuredbytheParkinson’sdiseasequestionnaire(PDQ-39)
[71].
In summary, PRE can signiﬁcantly improve muscle size,
muscle strength, muscle endurance, and neuromuscular
function and can signiﬁcantly impact areas often reported
to be problematic in individuals with PD, such as bradyki-
nesia, postural instability, and patient-perceived quality of
life.
4.Limitationsof CurrentResearch and
Recommendations for FutureResearch
The few studies that have examined the eﬀect of PRE in
PD are no doubt vital to our continued understanding of
the eﬀect of PRE and the pursuit of adjunct treatments for
PD; however, they are not without limitations. First, it is not
clear how anti-Parkinsonian medications interact with PRE.
To ascertain the unique contribution of PRE on strength
and functional outcomes in PD, it is essential to examine
individuals while oﬀ anti-Parkinsonian medications. Also,
if changes to the underlying disease process are to be
evaluated, this is best done while oﬀ medication. Among the
studies reviewed, all except for Scandalis and colleagues [79]
tested individuals with PD while on medication. Thus, more
research is required to investigate the unique eﬀect of PRE
on outcomes of strength, neuromuscular function, and the
underlying disease process.
Second, the motor UPDRS, which is the clinical gold
standard of assessing severity of motor deﬁcits in PD, has
rarely been used as an outcome measure while evaluating the
eﬀectsofPRE.Inordertoconvinceneurologistswhomanage
individuals with PD to prescribe exercise as an adjunct
therapy, it is vital to demonstrate clinically important change
on the motor UPDRS as a result of PRE. Minimal clinically
importantchangeonthemotorUPDRSisbasedontheeﬀect
of anti-Parkinsonian medication and is deﬁned as a 5-point
reduction on the motor UPDRS score [82]. The scores on
the motor UPDRS range from 0 to 108, and higher scores
indicate more severe motor symptoms. Thus, if exercise can
bringaboutatleasta5-pointreductioninthemotorUPDRS,
one can make a compelling case to include PRE as an adjunct
to the standard management of PD. Future research should
include the motor UPDRS as an outcome measure while
evaluating the eﬀects of PRE. To date, Dibble et al. [71]a n d
Hass et al. [77] have used the motor UPDRS as an outcome
measure; however, they both failed to show any clinically
relevant change following PRE. This could have been due to
the fact that these studies tested individuals with PD while
on medication and/or due to the short duration of the PRE
intervention.
Third, long-term eﬀects of PRE are yet to be determined.
All of the studies conducted to date evaluate the eﬀect of
PRE over 8 to 24 weeks. Given that PD is a progressive
neurodegenerative disorder and is further aﬀected by the
processofaging,whichisaccompaniedbydeclineinstrength
and neuromuscular function [83], it is vital that the long-
term eﬀects of PRE are thoroughly understood. For instance,
continued beneﬁt of PRE over the long-term could reduce
the rate at which the disease progresses. This is signiﬁcant,
especially because recent exciting epidemiological research
h a sc o n c l u d e dt h a tm o d e r a t et ov i g o r o u sl e v e l so fp h y s i c a l
activity in mid- or later life may be associated with a 40%
reduction in the future risk of being diagnosed with PD [84].
Additionally, PRE over the long term could reduce the rate at
which dosage of medication is increased and possibly delay
the onset of dyskinesias, as well as surgical interventions.
Thus, it is essential that future studies evaluate the eﬀects of
PRE over the long term in PD.Parkinson’s Disease 7
Fourth, even though it is accepted that cognitive impair-
ment is frequently observed in PD [85–90], the eﬀect of
PRE on cognitive function in PD is not well researched.
The rationale for PRE as a therapeutic intervention for
cognitive dysfunction is threefold. First, PRE has been found
to improve cognitive function in healthy subjects between
the age of 65 and 75. Cassilhas et al. demonstrated improved
performance on measures of working memory and attention
for those assigned to 24 weeks of PRE [91]. More recently,
Liu-Ambrose and colleagues demonstrated beneﬁcial cog-
nitive eﬀects of 52 weeks of PRE in community dwelling
elderlywomen[92].Theyshowedimprovementsinattention
and conﬂict resolution. Additionally, in a subsequent study
with the same sample, they demonstrated changes in percent
signal change in brain areas that correspond to conﬂict reso-
lution [50]. Second, even though aerobic training provides
cognitive beneﬁts, a combination of aerobic and PRE has
been evidenced to render the greatest cognitive beneﬁts [93].
Recently, two studies have evaluated the combined eﬀect of
PRE and aerobic exercise on executive function in PD [94,
95]. Both studies concluded that PRE combined with aerobic
exercise improved executive function. Third, there is a strong
biological basis for the cognitive beneﬁts gained from PRE.
These include the reduction in serum levels of homocysteine
[96] and the increase in serum levels of insulin-like growth
factor I [97], following PRE, which are both known to be
associated with cognitive function [98, 99]. Thus, there is
evidence in the literature to support the beneﬁcial eﬀects
of PRE on cognitive function, and future research should
address this in individuals with PD.
Fifth, the diverse experimental designs employed in the
studies reviewed may be less than ideal. Given the realities of
conducting research with a patient population, the studies
reviewed provide an excellent basis for large-scale, long-
term prospective randomized clinical trials. However, the
small sample sizes used (between 6 and 14 per group,
with a total sample size not exceeding 20), the lack of
rater blinding (only Hass et al.’s was a randomized, double-
blinded,placebo-controledtrial[77];whileHirschetal.’swas
a randomized control trial, the raters were unblinded [78]),
and not employing the intent-to-treat principle in statistical
analysis lead to biases that could question the validity of
some of the conclusions. Thus, future studies should be
blinded, randomized clinical trials, which will provide the
most robust experimental design to address the gaps in the
literaturebyassessingtheshort-andlong-termeﬀectsofPRE
in individuals with PD.
Sixth, the optimal PRE prescription for individuals with
PDisyettobeestablished.Therearetwoaspectsoftreatment
optimization. The ﬁrst aspect is the optimization of PRE
parameters, such as the frequency, intensity, duration, and
mode of exercise (i.e., strength and power training). The
second aspect is the optimization of PRE with regards to the
various clinical subtypes of PD. Within the general diagnosis
of PD, distinct clinical subtypes have been identiﬁed based
in part on the age of onset, the predominant motor sign
(e.g., tremor dominant, nontremor-dominant akinetic rigid
etc.), and the clinical course of the disease [100]. There is
evidence in the literature that suggests that these diﬀerent
PD subtypes may respond diﬀerently to interventions and
may progress at diﬀerent rates [101–103]. For example,
individuals who begin with signiﬁcant rest tremor may not
respond as well to levodopa and may progress at a slower
rate compared to individuals who present with a nontremor-
dominant, akinetic-rigid form of the disease. It is likely that
the eﬀect of PRE may vary with the clinical subtype of PD.
In addition, the eﬀect of PRE on tremor and rigidity is
not yet known. Thus, future research should identify the
optimal PRE prescription in the context of the diﬀerent
clinical subtypes of individuals with PD and empirically
verify hypotheses related to tremor and rigidity as well.
5. Conclusion
In PD, bradykinesia and muscle weakness are primarily
due to nigral dopaminergic deﬁcits that alter corticospinal
activation. Given the wide array of neural changes that
accompany PRE summarized in this paper, the potential to
slow the rate of the progression of the symptoms of PD,
the improvement in strength and function, and the positive
eﬀects on nonmotor symptoms of PD, there is a strong
rationale for the use of PRE as an adjunct treatment in PD.
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